Oppenheimer & Co. Inc. Grows Position in Regeneron Pharmaceuticals, Inc. $REGN

Oppenheimer & Co. Inc. lifted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.5% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 24,792 shares of the biopharmaceutical company’s stock after buying an additional 1,078 shares during the quarter. Oppenheimer & Co. Inc.’s holdings in Regeneron Pharmaceuticals were worth $19,136,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of REGN. WPG Advisers LLC raised its stake in Regeneron Pharmaceuticals by 312.5% during the fourth quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 25 shares in the last quarter. Salomon & Ludwin LLC purchased a new stake in Regeneron Pharmaceuticals during the third quarter valued at $27,000. Board of the Pension Protection Fund purchased a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at $31,000. Caitlin John LLC purchased a new stake in Regeneron Pharmaceuticals during the third quarter valued at $34,000. Finally, FNY Investment Advisers LLC purchased a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at $38,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

More Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Q1 results beat expectations: Regeneron reported Q1 revenue up 19% to ~$3.6B and non?GAAP EPS of $9.47, beating estimates, driven by strong Dupixent demand and Libtayo. This underpins near?term top?line momentum. Reuters: Regeneron beats quarterly results
• Positive Sentiment: $3 billion buyback announced and dividend declared: Management authorized up to $3B in share repurchases and declared a $0.94 quarterly dividend, both shareholder-friendly actions that support EPS and investor returns. Seeking Alpha: buyback mention
• Positive Sentiment: Pipeline progress could drive medium?term upside: Management reported C5 program milestones (pivotal PNH enrollment complete, positive Phase III for cemdisiran in gMG) and potential multi?indication launches as soon as late?2026 — important optionality beyond core franchises. Yahoo: C5 milestones & pipeline
• Neutral Sentiment: Analyst target adjustments but mixed ratings: Several shops trimmed price targets (RBC to $762, Wells Fargo to $800, Truist to $796, Barclays to $917) while many retained buy/overweight stances — suggests analysts are tuning models post?earnings but still see upside. TickerReport/Benzinga: price target moves
• Neutral Sentiment: Analysts trimmed near?term forecasts: Firms modestly cut forecasts after Q1, reflecting product mix and competitive assumptions; important to watch updated guidance and modeling revisions. Benzinga: analysts cut forecasts
• Negative Sentiment: Market punished stock on Eylea weakness and competitive risk: U.S. high?dose Eylea sales underperformed expectations and competition in the retina market is intensifying — this drove the immediate post?earnings weakness despite the beat. Yahoo: Eylea sales miss
• Negative Sentiment: Q1 net income decline: GAAP net income fell ~10% to $727M year?over?year, reflecting some one?time items and mix; investors sensitive to margin and profitability trends may see this as a near?term headwind. Pharma?Technology: net income falls

Regeneron Pharmaceuticals Trading Up 3.0%

REGN stock opened at $707.06 on Friday. The company has a quick ratio of 3.39, a current ratio of 4.15 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $821.11. The stock has a market capitalization of $74.75 billion, a price-to-earnings ratio of 17.23, a price-to-earnings-growth ratio of 1.58 and a beta of 0.40. The firm’s fifty day simple moving average is $756.81 and its two-hundred day simple moving average is $735.17.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, beating analysts’ consensus estimates of $8.91 by $0.56. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The business had revenue of $3.61 billion for the quarter, compared to analysts’ expectations of $3.48 billion. During the same quarter in the previous year, the business posted $8.22 earnings per share. The business’s revenue was up 19.0% compared to the same quarter last year. As a group, analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.98 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 4th. Shareholders of record on Wednesday, May 20th will be given a dividend of $0.94 per share. The ex-dividend date is Wednesday, May 20th. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is 9.16%.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on REGN shares. Bank of America raised shares of Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and upped their price target for the company from $627.00 to $860.00 in a research note on Wednesday, January 7th. Truist Financial decreased their price target on shares of Regeneron Pharmaceuticals from $801.00 to $796.00 and set a “buy” rating on the stock in a research note on Thursday. Piper Sandler started coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, March 31st. They set an “overweight” rating and a $875.00 price target on the stock. Royal Bank Of Canada decreased their price target on shares of Regeneron Pharmaceuticals from $779.00 to $762.00 and set a “sector perform” rating on the stock in a research note on Thursday. Finally, Oppenheimer reiterated an “outperform” rating and set a $865.00 price objective (up from $750.00) on shares of Regeneron Pharmaceuticals in a research report on Monday, February 2nd. Two research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $825.68.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, SVP Jason Pitofsky sold 2,036 shares of the company’s stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $778.52, for a total value of $1,585,066.72. Following the transaction, the senior vice president directly owned 4,272 shares in the company, valued at approximately $3,325,837.44. This represents a 32.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Huda Y. Zoghbi sold 1,638 shares of the company’s stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the completion of the transaction, the director owned 1,703 shares in the company, valued at approximately $1,330,604.99. The trade was a 49.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 3,774 shares of company stock worth $2,942,738 over the last quarter. Insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.